FineTech Laboratories Overview
- Founded
- 1990

- Status
- Acquired/Merged
- Latest Deal Type
- M&A
- Financing Rounds
- 5
FineTech Laboratories General Information
Description
Developer of active pharmaceutical ingredients created to process and polymorph patents by developing non-infringing processes or polymorphs. The company's active pharmaceutical ingredients include cabergoline, latanoprost, travoprost, nabilone, melatonin and methylbenzethonium chloride, enabling the healthcare sectors to access a wide range of products and services to fulfill their needs and develop their sectors under one roof.
Contact Information
(Operating Subsidiary)
- 33, Hanarkissim Street
- Nesher 36608
- Israel
FineTech Laboratories Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore FineTech Laboratories‘s full profile, request access.
Request a free trialFineTech Laboratories Executive Team (1)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Arie Gutman Ph.D | Founder, Chief Executive Officer & President |
FineTech Laboratories Former Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore FineTech Laboratories‘s full profile, request access.
Request a free trial